

ASX ANNOUNCEMENT

Monday 21 June 2021

Palla Pharma appoints Alloga securing access to wide UK distribution network

Palla Pharma Limited (ASX:PAL) ("the Company"), a fully integrated opiate manufacturer and supplier to the global pain relief market, is pleased to announce that it has appointed pan-European healthcare logistics provider Alloga UK Limited ("Alloga") as its exclusive provider of pre-wholesale supply chain services for its products in the United Kingdom.

Brendan Middleton, Interim CEO commented:

"We have successfully completed the extensive Alloga qualification and onboarding process and are now able to access Alloga's distribution network including 6 major UK wholesale groups which supply to 70% of the UK Co-Codamol retail market. In addition, Alloga's international healthcare supply chain network offers a pan-European delivery capability, and the Company will look to further leverage its partnership with Alloga as it launches products into other major European markets."

Overview of Alloga

Alloga is a leading provider of specialist healthcare logistics solutions and part of Alliance Healthcare, a Walgreen Boots Alliance business (which was acquired by AmerisourceBergen on 2 June 2021). Their client list and distribution network includes some of the largest blue-chip pharmaceutical companies in the UK, with a multi-user environment supporting over 150 clients, including over 30 of the top 50 UK pharmaceutical companies, and distributing goods worth over £7 billion per year to wholesalers, pharmacies, hospitals, supermarkets, and other retailers.

This announcement has been approved for release by the Board of Directors.

For more information please contact:

Simon Moore Chairman Palla Pharma Limited +61 3 9301 0800 Brendan Middleton Interim CEO Palla Pharma Limited +61 3 9301 0800 Adrian Mulcahy Investor Relations Market Eye +61 438 630 422 ir@pallapharma.com



About Palla Pharma Limited:

Palla Pharma Limited (ASX:PAL) is a vertically integrated opiate manufacturer from poppy straw growing through to tableting production. Palla Pharma has developed an innovative, efficient, and environmentally sustainable opiate manufacturing process based on a unique water-based extraction technology. The company is one of six licensed opiate producers globally, and one of three fully integrated suppliers from opiate extraction through to tableting production delivering on its strategy to secure access to regulated downstream narcotics markets by leveraging its production cost advantage.